Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
IGM Biosciences, Inc.
Rutgers, The State University of New Jersey
Valerio Therapeutics
National Cancer Institute (NCI)
Case Comprehensive Cancer Center